Journal ArticleDOI
Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them
Gary G. Koch,Catherine M. Tangen,Catherine M. Tangen,Jin Whan Jung,Jin Whan Jung,Ingrid A. Amara,Ingrid A. Amara +6 more
TLDR
The critical consideration for studies with covariance analyses planned as the primary method for comparing treatments is the specification of the covariables in the protocol (or in an amendment or formal plan prior to any unmasking of the study).Abstract:
Analysis of covariance is an effective method for addressing two considerations for randomized clinical trials. One is reduction of variance for estimates of treatment effects and thereby the production of narrower confidence intervals and more powerful statistical tests. The other is the clarification of the magnitude of treatment effects through adjustment of corresponding estimates for any random imbalances between the treatment groups with respect to the covariables. The statistical basis of covariance analysis can be either non-parametric, with reliance only on the randomization in the study design, or parametric through a statistical model for a postulated sampling process. For non-parametric methods, there are no formal assumptions for how a response variable is related to the covariables, but strong correlation between response and covariables is necessary for variance reduction. Computations for these methods are straightforward through the application of weighted least squares to fit linear models to the differences between treatment groups for the means of the response variable and the covariables jointly with a specification that has null values for the differences that correspond to the covariables. Moreover, such analysis is similarly applicable to dichotomous indicators, ranks or integers for ordered categories, and continuous measurements. Since non-parametric covariance analysis can have many forms, the ones which are planned for a clinical trial need careful specification in its protocol. A limitation of non-parametric analysis is that it does not directly address the magnitude of treatment effects within subgroups based on the covariables or the homogeneity of such effects. For this purpose, a statistical model is needed. When the response criterion is dichotomous or has ordered categories, such a model may have a non-linear nature which determines how covariance adjustment modifies results for treatment effects. Insight concerning such modifications can be gained through their evaluation relative to non-parametric counterparts. Such evaluation usually indicates that alternative ways to compare treatments for a response criterion with adjustment for a set of covariables mutually support the same conclusion about the strength of treatment effects. This robustness is noteworthy since the alternative methods for covariance analysis have substantially different rationales and assumptions. Since findings can differ in important ways across alternative choices for covariables (as opposed to methods for covariance adjustment), the critical consideration for studies with covariance analyses planned as the primary method for comparing treatments is the specification of the covariables in the protocol (or in an amendment or formal plan prior to any unmasking of the study.read more
Citations
More filters
Book
Causal Inference for Statistics, Social, and Biomedical Sciences: An Introduction
Guido W. Imbens,Donald B. Rubin +1 more
TL;DR: In this paper, two world-renowned experts present statistical methods for studying causal in nature: what would happen to individuals, or to groups, if part of their environment were changed?
Journal ArticleDOI
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Lon S. Schneider,Pierre N. Tariot,Karen S. Dagerman,Sonia M. Davis,John K. Hsiao,M. Saleem Ismail,Barry D. Lebowitz,Constantine G. Lyketsos,J. Michael Ryan,T. Scott Stroup,David L. Sultzer,Daniel Weintraub,Jeffrey A. Lieberman +12 more
TL;DR: Adverse effects offset advantages in the efficacy of atypical antipsychotic drugs for the treatment of psychosis, aggression, or agitation in patients with Alzheimer's disease.
Journal ArticleDOI
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial
TL;DR: Tenecteplase and alteplase were equivalent for 30-day mortality and the ease of administration of tenectePLase may facilitate more rapid treatment in and out of hospital.
Journal ArticleDOI
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
Hillel Panitch,Douglas S. Goodin,Gordon S. Francis,P Chang,Patricia K. Coyle,Paul O'Connor,Edward Monaghan,David K.B. Li,Brian G. Weinshenker +8 more
TL;DR: IFNβ-1a 44 μg subcutaneously tiw was more effective than IFNβ -1a 30 μg IM qw on all primary and secondary outcomes investigated after 24 and 48 weeks of treatment.
Journal ArticleDOI
Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension: A Randomized Controlled Clinical Trial
Vallerie V. McLaughlin,Raymond L. Benza,Lewis J. Rubin,Richard N. Channick,Robert Voswinckel,Victor F. Tapson,Ivan M. Robbins,Horst Olschewski,Melvyn Rubenfire,Werner Seeger +9 more
TL;DR: In this article, the efficacy and safety of inhaled treprostinil in pulmonary arterial hypertension (PAH) patients receiving therapy with either bosentan or sildenafil were assessed.